期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

以血管内皮生长因子及其受体为靶点的肿瘤血管生成抑制剂的研究进展 被引量：7

Advance in tumor angiogenesis inhibitors targeting VEGF and its receptors
暂未订购
导出
摘要 肿瘤的生长和转移依赖于新生血管的形成,血管内皮生长因子(VEGF)在肿瘤新生血管形成中起关键作用。以VEGF及其受体为靶点,通过抑制肿瘤血管生长,从而遏制肿瘤的生长和转移的研究已经取得了一定的成果,在此对肿瘤血管生成抑制剂(TAI)的研究进展进行综述。 Tumor growth and metastasis largely depend on angiogenesis and the vascular endothelial growth factor（VEGF） play a critical rule in tumor-assoclated angiogenesis. Targeting VEGF and its receptors, preventing the expansion of new blood vessel networks results in reduced tumor size and metastases. Some progress has been achieved in this field and recent developments of tumor angiogenesis inhibitors（TAI） targeting VEGF and its receptors were reviewed in this article.
作者 翟鑫 王玉亚 宫平
机构地区 沈阳药科大学制药工程学院
出处 《中国药物化学杂志》 CAS CSCD 2006年第1期60-64,共5页 Chinese Journal of Medicinal Chemistry
关键词 药物化学 血管生成 综述 血管内皮生长因子 血管内皮生长因子受体 TAI medicinal chemistry angiogenesis review VEGF VEGF receptors TAI
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献21

  • 1Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs [ J ].Lancet Oncol, 2001,2 (5) : 278 - 289.
  • 2Folman J. What is the evidence that tumors are angiogenesis-dependent? [J].J Natl Cancer Inst, 1990,82(1) :4 - 6.
  • 3Burke PA, deNardo SJ. Antiangiogenic agents and their proming potential in combined therapy [ J ]. Rev Oncol Hemat, 2001,39( 1 - 2) : 155 - 171.
  • 4Carmeliet P. Angiogenesis in health and disease[J].Nat Med, 2003, 9(6) :653 - 660.
  • 5陈军,朱驹,李卡,宋云龙.血管内皮细胞生长因子受体酪氨酸激酶抑制剂[J].药学进展,2002,26(6):329-333. 被引量：5
  • 6Sun L, Tran N, Hang C, et al. Design, synthesis, and evaluations of substituted 3-[ (3- or 4-caxboxyexhylpyrrol-2-yl) methylidenyl] indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases[J]. J Med Chem, 1999, 42(25) : 5120 - 5130.
  • 7Carter SK. Clinical strategy for the development of angiogenesis inhibition [ J ]. Oncologist, 2000, 5 ( suppl1) :51 - 54.
  • 8Laird AD, Vajkoezy P, Shawver LK, et al, SU6668 is a potent antlagiogenic and antitumor agent that induces regression of established tumors [ J ]. Cancer Res, 2000, 60(15) :4152 - 4160.
  • 9Motzer RJ, Rini BI, Michaelson MD, et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumour activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase Ⅱ trial[C]. USA:Proe Am Soc Clin Oneol, 2004:381.
  • 10Zips D, Krause M, Heasd F, et al. Experimental study on different combination schedules of VEGF receptor inhibitor PTK787/ZK222584 and fractionated irradiation [ J ]. Anticancer Res, 2003, 23 (5A) : 3869 -3876.

二级参考文献17

  • 1Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors[J]. Cancer Res, 2000,60(15):4152-4160.
  • 2Hennequin LF, Thomas AP, Johnstone C, et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors[J]. J Med Chem, 1999,42(26):5369-5389.
  • 3Hennequin LF, Stokes ES, Thomas AP, et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors[J]. J Med Chem, 2002,45(6):1300-1312.
  • 4Wedge SR, Ogilvie DJ, Dukes M, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy[J]. Cancer Res, 2000,60(4):970-975.
  • 5Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration[J]. Cancer Res, 2002,62(16):4645-4655.
  • 6Bold G, Altmann KH, Frei J, et al. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis[J]. J Med Chem, 2000,43(12):2310-2323.
  • 7Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration[J]. Cancer Res, 2000,60(8):2178-2189.
  • 8Folkman J. What is the evidence that tumors are angiogenesis dependent[J]. J Natl Cancer Inst, 1990,82(1):4-6.
  • 9Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor[J]. Endocr Rev, 1997,18(1):4-25.
  • 10de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor[J]. Science, 1992,255(5047):989-991.

共引文献4

同被引文献94

引证文献7

二级引证文献40

中国药物化学杂志
2006年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部